Education
About Us
Working with TipRanks
Follow Us
PuraPharm Corp. Ltd. (HK:1498)
:1498
RESEARCH TOOLSreports
1498 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$0.43 - HK$0.85
Previous CloseN/A
Volume23.50K
Average Volume (3M)167.53K
Market Cap
HK$179.70M
Enterprise ValueHK$528.74M
Total Cash (Recent Filing)HK$12.79M
Total Debt (Recent Filing)HK$363.76M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Sep 02, 2025EPS EstimateN/A
Last Dividend Ex-Date
May 31, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding395,897,280
10 Day Avg. Volume224,900
30 Day Avg. Volume167,533
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)1.60
Price to Sales (P/S)0.00
P/FCF Ratio1.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$0.50Price Target Upside8.70% Upside
Rating ConsensusHold
Number of Analyst Covering0
PuraPharm Corp. Ltd. News
PremiumCompany Announcements
PuraPharm Announces Patent Licence and Share Subscription Agreements
PremiumCompany Announcements
PuraPharm Issues Profit Warning Amid Rising Costs and Market Challenges
PremiumCompany Announcements
PuraPharm Faces Compliance Challenges After Director Resignation
PremiumCompany Announcements
PuraPharm Announces Board of Directors and Roles
PremiumCompany Announcements
PuraPharm Announces Lapse of Disposal Agreement
PremiumCompany Announcements
PuraPharm Appoints Dr. Kam Biu Tsoi as Executive Director
PremiumCompany Announcements
PuraPharm Announces Board Composition and RolesPremiumCompany Announcements
PuraPharm Updates Nomination Committee Terms to Enhance Governance1498 FAQ
What was PuraPharm Corp. Ltd.’s price range in the past 12 months?
PuraPharm Corp. Ltd. lowest stock price was HK$0.43 and its highest was HK$0.85 in the past 12 months.
What is PuraPharm Corp. Ltd.’s market cap?
PuraPharm Corp. Ltd.’s market cap is HK$179.70M.
When is PuraPharm Corp. Ltd.’s upcoming earnings report date?
PuraPharm Corp. Ltd.’s upcoming earnings report date is Sep 02, 2025 which is in 37 days.
How were PuraPharm Corp. Ltd.’s earnings last quarter?
PuraPharm Corp. Ltd. released its earnings results on Mar 31, 2025. The company reported -HK$0.042 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.042.
Is PuraPharm Corp. Ltd. overvalued?
According to Wall Street analysts PuraPharm Corp. Ltd.’s price is currently Undervalued.
Does PuraPharm Corp. Ltd. pay dividends?
PuraPharm Corp. Ltd. pays a Annually dividend of HK$0.019 which represents an annual dividend yield of N/A. See more information on PuraPharm Corp. Ltd. dividends here
What is PuraPharm Corp. Ltd.’s EPS estimate?
PuraPharm Corp. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PuraPharm Corp. Ltd. have?
PuraPharm Corp. Ltd. has 395,897,280 shares outstanding.
What happened to PuraPharm Corp. Ltd.’s price movement after its last earnings report?
PuraPharm Corp. Ltd. reported an EPS of -HK$0.042 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5%.
Which hedge fund is a major shareholder of PuraPharm Corp. Ltd.?
Currently, no hedge funds are holding shares in HK:1498
PuraPharm Corp. Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
HK$0.50 (8.70% Upside)
HK$0.50 (8.70% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.91%
12-Months-Change
Fundamentals
Return on Equity
-26.80%
Trailing 12-Months
Asset Growth
-15.19%
Trailing 12-Months
Company Description
PuraPharm Corp. Ltd.
PuraPharm Corp. Ltd. (1498) is a leading pharmaceutical company primarily focused on the research, development, manufacture, and sale of Chinese medicine products. It operates in the healthcare and wellness sectors, offering a broad range of products including Chinese medicine granules, Chinese medicine services, and health supplements. The company is committed to integrating traditional Chinese medicine with modern scientific techniques to enhance its product offerings and improve healthcare outcomes.
Technical Analysis
Huakang Biomedical Holdings Company Limited
―
Fusen Pharmaceutical Co., Ltd.
―
Kontafarma China Holdings Ltd
―
China NT Pharma Group Co., Ltd.
―
Extrawell Pharmaceutical Holdings Limited
―